Clinical trials: WHIM
Neutropenia
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
This is a 2-part study of mavorixafor in participants diagnosed with chronic neutropenia. The main goal of Part 1 (Phase 1b) is to help researchers learn more about how the investigational medicine, mavorixafor, impacts people…
- Trial name
- NCT04154488
- Testing
- Mavorixafor
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- X4 Pharmaceuticals
Primary Hyperaldosteronism, Aldosterone-Producing Adenoma
[18F]AlF-NOTA-pentixather PET/CT in Patients With Suspected Primary Hyperaldosteronism
The study was proposed to include 20 patients with clinical suspicion of primary aldosteronism for [18F]AlF-NOTA-pentixather PET/CT imaging and to analyze the specificity and sensitivity of [18F]AlF-NOTA-pentixather PET/CT for…
- Trial name
- NCT05815069
- Testing
- [18F]AlF-NOTA-pentixather PET/CT
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Multiple Myeloma
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Multiple myeloma is a disease mainly located in participants bones. Usually a participants physician arrives at this diagnosis by doing blood tests and ordering standard of care imaging tests (18F-FDG PET/CT and maybe additional…
- Trial name
- NCT06871176
- Testing
- [68Ga]Ga-PentixaFor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
HIV Infections
Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients
New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV drugs.
- Trial name
- NCT00089466
- Testing
- AMD11070
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelokathexis, Infections
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Background: WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare disease. It can cause cancers, infections, and warts. Researchers want to see if a drug called plerixafor can treat WHIMS.
- Conditions
- Myelokathexis, Infections, Neutropenia, Warts
- Trial name
- NCT02231879
- Testing
- Plerixafor, G-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neoplasm Malignant
"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.
This is multicentric, interventional, non farmacological and prospective study.
- Trial name
- NCT05818865
- Testing
- CLG
- Where
- 2 sites in Italy
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute, Naples
Healthy Volunteers
An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers
This study will determine how safely and well people can tolerate AMD3100 at larger than normal doses to mobilize CD34+ cells, (stem cells).
- Trial name
- NCT00322127
- Testing
- AMD3100
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Healthy
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than the use of G-CSF alone.
- Trial name
- NCT00082329
- Testing
- AMD 3100 (Mozobil plerixafor), Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies.
- Trial name
- NCT04684472
- Testing
- Modified anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Liqun Zou
Solid Tumor
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory…
- Trial name
- NCT02737072
- Testing
- LY2510924, Durvalumab
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) is a particularly aggressive type of breast cancer that is difficult to treat. Unlike other forms of breast cancer, TNBC tends to relapse earlier and spread more quickly to other parts of the…
- Trial name
- EXIGENCE (NCT06962163)
- Testing
- [68Ga]Ga-PentixaFor PET/CT
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Institut Cancerologie de l'Ouest
Thymoma
Application of 68Ga-Pentixafor PET/CT for Thymoma
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy.
- Trial name
- NCT06086327
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Sickle Cell Disease
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation.
- Trial name
- NCT05618301
- Testing
- Motixafortide, Natalizumab, Leukapheresis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
HIV Infections
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who…
- Trial name
- NCT00063804
- Testing
- Ritonavir, AMD070
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Waldenstrom Macroglobulinemia
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
In Waldenström macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of short duration compared to other indolent lymphomas.
- Trial name
- CZAR-1 (NCT04263480)
- Testing
- Carfilzomib + Ibrutinib, Ibrutinib
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 99 people
- Sponsor
- Christian Buske
Small Cell Lung Cancer
CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer
This prospective observational study aims to evaluate the clinical value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC).
- Trial name
- NCT07316309
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shandong Cancer Hospital and Institute
Lymphoma, Multiple Myeloma
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia
- Trial name
- NCT04504526
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
The purpose of this study is to evaluate the disease free survival and the overall survival in patients with acute leukemia in first or second complete remission after administrating a CXCR4 antagonist, as a chemo sensitization…
- Trial name
- NCT02605460
- Testing
- Busulfan, Cyclophosphamide, CXCR4 Antagonist
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Hiv
Autologous CD4 T-Cells in HIV (C34-CXCR4)
A single cohort, open-label pilot study of the safety and tolerability of a single infusion of autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector in…
- Trial name
- NCT03020524
- Testing
- Autologous CD4 T-Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Metastatic Pancreatic Cancer
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
- Trial name
- NCT04177810
- Testing
- Cemiplimab, Plerixafor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins